Stefano Crippa, Giuseppe Malleo, Serena Langella, Claudio Ricci, Fabio Casciani, Giulio Belfiori, Sara Galati, Carlo Ingaldi, Gabriella Lionetto, Alessandro Ferrero, Riccardo Casadei, Giorgio Ercolani, Roberto Salvia, Massimo Falconi, Alessandro Cucchetti
{"title":"Cure Probabilities After Resection of Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Analysis of 2554 Patients.","authors":"Stefano Crippa, Giuseppe Malleo, Serena Langella, Claudio Ricci, Fabio Casciani, Giulio Belfiori, Sara Galati, Carlo Ingaldi, Gabriella Lionetto, Alessandro Ferrero, Riccardo Casadei, Giorgio Ercolani, Roberto Salvia, Massimo Falconi, Alessandro Cucchetti","doi":"10.1097/SLA.0000000000006166","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To assess the probability of being cured of pancreatic ductal adenocarcinoma (PDAC) by pancreatic surgery.</p><p><strong>Background: </strong>Statistical cure implies that a patient treated for a specific disease will have the same life expectancy as if he/she never had that disease.</p><p><strong>Methods: </strong>Patients who underwent pancreatic resection for PDAC between 2010 and 2021 were retrospectively identified using a multi-institutional database. A nonmixture statistical cure model was applied to compare disease-free survival to the survival expected for a matched general population.</p><p><strong>Results: </strong>Among 2554 patients, either in the setting of upfront (n=1691) or neoadjuvant strategy (n=863), the cure model showed that the probability that surgery would offer the same life expectancy (and tumor-free) as the matched general population was 20.4% (95% CI: 18.3, 22.5). Cure likelihood reached the 95% of certainty (time to cure) after 5.3 years (95% CI: 4.7, 6.0). A preoperative model was developed based on tumor stage at diagnosis ( P =0.001), radiologic size ( P =0.001), response to chemotherapy ( P =0.007), American Society of Anesthesiology class ( P =0.001), and preoperative Ca19-9 ( P =0.001). A postoperative model with the addition of surgery type ( P =0.015), pathologic size ( P =0.001), tumor grading ( P =0.001), resection margin ( P =0.001), positive lymph node ratio ( P =0.001), and the receipt of adjuvant therapy ( P =0.001) was also developed.</p><p><strong>Conclusions: </strong>Patients operated for PDAC can achieve a life expectancy similar to that of the general population, and the likelihood of cure increases with the passage of recurrence-free time. An online calculator was developed and available at https://aicep.website/?cff-form=15 .</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"999-1005"},"PeriodicalIF":7.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/SLA.0000000000006166","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To assess the probability of being cured of pancreatic ductal adenocarcinoma (PDAC) by pancreatic surgery.
Background: Statistical cure implies that a patient treated for a specific disease will have the same life expectancy as if he/she never had that disease.
Methods: Patients who underwent pancreatic resection for PDAC between 2010 and 2021 were retrospectively identified using a multi-institutional database. A nonmixture statistical cure model was applied to compare disease-free survival to the survival expected for a matched general population.
Results: Among 2554 patients, either in the setting of upfront (n=1691) or neoadjuvant strategy (n=863), the cure model showed that the probability that surgery would offer the same life expectancy (and tumor-free) as the matched general population was 20.4% (95% CI: 18.3, 22.5). Cure likelihood reached the 95% of certainty (time to cure) after 5.3 years (95% CI: 4.7, 6.0). A preoperative model was developed based on tumor stage at diagnosis ( P =0.001), radiologic size ( P =0.001), response to chemotherapy ( P =0.007), American Society of Anesthesiology class ( P =0.001), and preoperative Ca19-9 ( P =0.001). A postoperative model with the addition of surgery type ( P =0.015), pathologic size ( P =0.001), tumor grading ( P =0.001), resection margin ( P =0.001), positive lymph node ratio ( P =0.001), and the receipt of adjuvant therapy ( P =0.001) was also developed.
Conclusions: Patients operated for PDAC can achieve a life expectancy similar to that of the general population, and the likelihood of cure increases with the passage of recurrence-free time. An online calculator was developed and available at https://aicep.website/?cff-form=15 .
期刊介绍:
The Annals of Surgery is a renowned surgery journal, recognized globally for its extensive scholarly references. It serves as a valuable resource for the international medical community by disseminating knowledge regarding important developments in surgical science and practice. Surgeons regularly turn to the Annals of Surgery to stay updated on innovative practices and techniques. The journal also offers special editorial features such as "Advances in Surgical Technique," offering timely coverage of ongoing clinical issues. Additionally, the journal publishes monthly review articles that address the latest concerns in surgical practice.